Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals (ASX: RCE), is a biotech company focused on developing innovative synthetic anti-infectives aimed at addressing the global challenge of antibiotic-resistant superbugs, such as sepsis.
The company's flagship products, RECCE® 327 (R327) for bacterial infections and RECCE® 529 for viral infections, specifically targets these resistant pathogens, and positions the company as a critical contributor to global health solutions.
Recce Pharmaceuticals History
Founded by Dr. Graham Melrose in 2008, Recce Pharmaceuticals (ASX: RCE) emerged from his extensive experience at Johnson & Johnson, leverages Dr. Melrose's pioneering research to create new classes of synthetic anti-infectives. It was named Recce (pronounced 'Wreck-key') because Recce is the standard military shortening of the word 'reconnaissance'. It intended to have a military-like impact on superbugs.
The company was listed in 2016, and over the years, Recce has advanced its drug candidates, through the clinic. R327 is the candidate that is most advanced. The drug, which can be administered topically or intravenously, has a Unique Mechanism of Action, working fast and continuing to work just as effectively with repeated use. Endurance is something existing antimicrobal solutions tend to stumble at, especially when bacteria mutates. Mutation is where the sequence of bacteria alters and one of the consequential effects can be resistance to antibiotics.
As of April 2025, the company has several clinical trials underway but the most important is a Phase 3 trial underway in Indonesia for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) – a term including several conditions including diabetic foot infections (DFI) and postoperative wound infections. This followed successful Phase 2 results in 2024.
Future Outlook of Recce Pharmaceuticals (ASX: RCE)
Recce Pharmaceuticals Ltd (ASX: RCE) has a bright future ahead of it, assuming it can advance its drugs through the clinic and onto the market.
The key catalysts for the company will be the results from the Phase III trial in Indonesia. Recce has told investors that it could have R327G commercialised in 2026 if this trial is successful.
Indonesia and the broader ASEAN region is a lucrative opportunity. Antimicrobial resistance (AMR) is a significant problem in that part of the world just as much as it is in the West, with costs related to AMR anticipated to reach US$550-700bn without any further interventions. Consider that Indonesia has a 12% prevalence of DFIs in hospitals and 24% in community settings. In the US, these figures are just 1.4% and 5.9% respectively.
Is Recce Pharmaceuticals (ASX: RCE) a Good Stock to Buy?
Recce appears promising, but it is not necessarily suitable for all investors. As with all clinical-stage biotechs, there is the risk of clinical trial failure and this could result in a significant retreat in the company's valuation. It is also not one for dividend investors because it does not pay a dividend.
However, the company carries less risk than many of its peers because it has multiple clinical trials underway and some of these are at more advanced stages than its peers.
Our Stock Analysis
Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs
For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best…
Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval
The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However,…
Recce Pharmaceuticals investors are excited despite the market volatility – and there’s good reason
Recce Pharmaceuticals investors are amongst the few investors in ASX stocks that have a reason to smile right now. Their…
These ASX biotechs are working with the US Department of Defence to bring new drugs to market and have a bright future ahead
Think of ASX stocks working with the US Department of Defence, and investors might imagine defence stocks or perhaps even…
How to minimise the risks of biotech shares on the ASX? Here are 4 traits investors should look for
To minimise the risks of biotech shares is a major challenge for investors, but not one that is insurmountable. The…
Recce Pharmaceuticals (ASX:RCE): Taking the fight against superbugs to the next level
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Sydney-based company fighting the battle against superbugs, with a legitimate chance of succeeding if…
- « Previous
- 1
- 2
- 3
- Next »
Frequently Asked Questions
James Graham, who has been with the company for several years.